Literature DB >> 21036369

Less invasive versus conventional double-valve surgery: a propensity-matched comparison.

Fernando A Atik1, Lars G Svensson, Eugene H Blackstone, A Marc Gillinov, Jeevanantham Rajeswaran, Bruce W Lytle.   

Abstract

OBJECTIVE: Less invasive approaches to double-valve surgery are used for improved cosmesis; however, few studies have investigated their effect on outcome. We sought to compare these less invasive approaches with conventional full sternotomy.
METHODS: From January 1995 to January 2004, 114 patients underwent primary double-valve surgery through a less invasive approach and 381 through conventional sternotomy. Because there were important differences in the patients' characteristics, a propensity score based on 42 factors was used to obtain 81 well-matched patient pairs (71% of possible matches) for comparison of in-hospital morbidity and mortality, mediastinal drainage, transfusion requirements, pulmonary function, pain, and long-term survival.
RESULTS: In-hospital mortality was similar for propensity-matched patients: 6.2% (5/81) for those undergoing less invasive surgery and 2.5% (2/81) for those undergoing conventional sternotomy (P > .4). Occurrences of stroke (P > .9), renal failure (P = .4), myocardial infarction (P > .9), and infection (P > .9) were also similar. However, 24-hour mediastinal drainage was less after less invasive surgery (median, 250 vs 400 mL; P < .0001), but a similar proportion of patients received transfusions (28% vs 40%, P = .2). An equivalent proportion of patients were extubated in the operating room (7.7% vs 7.0%, P > .9), and median hours to extubation were similar (5.0 vs 6.5 hours). Pain scores were equivalent (P > .3). Long-term survival was also similar (82% and 76% at 10 years, P = .07).
CONCLUSIONS: Within that portion of the spectrum of double-valve surgery in which propensity matching was possible, less invasive surgery had cosmetic and blood product use advantages over conventional surgery and no apparent detriments.
Copyright © 2011 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21036369     DOI: 10.1016/j.jtcvs.2010.05.053

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Minimally invasive aortic valve surgery: Cleveland Clinic experience.

Authors:  Douglas R Johnston; Eric E Roselli
Journal:  Ann Cardiothorac Surg       Date:  2015-03

2.  Outcomes of minimally invasive double valve surgery.

Authors:  Orlando Santana; Steve Xydas; Roy F Williams; Angelo LaPietra; Maurice Mawad; Frederick Hasty; Esteban Escolar; Christos G Mihos
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

3.  Minimally invasive approach provides at least equivalent results for surgical correction of mitral regurgitation: a propensity-matched comparison.

Authors:  Andrew B Goldstone; Pavan Atluri; Wilson Y Szeto; Alen Trubelja; Jessica L Howard; John W MacArthur; Craig Newcomb; Joseph P Donnelly; Dale M Kobrin; Mary A Sheridan; Christiana Powers; Robert C Gorman; Joseph H Gorman; Alberto Pochettino; Joseph E Bavaria; Michael A Acker; W Clark Hargrove; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2013-03       Impact factor: 5.209

Review 4.  Minimally invasive valve surgery in high-risk patients.

Authors:  Orlando Santana; Steve Xydas; Roy F Williams; S Howard Wittels; Evin Yucel; Christos G Mihos
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

5.  Aortic valve replacement in patients with a left ventricular ejection fraction ≤35% performed via a minimally invasive right thoracotomy.

Authors:  Orlando Santana; Steve Xydas; Roy F Williams; Angelo La Pietra; Maurice Mawad; Vicente Behrens; Esteban Escolar; Christos G Mihos
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

6.  A Simple Approach for Minimally Invasive Combined Aortic and Mitral Valve Surgery.

Authors:  Hesham Alkady; Sobhy Abouramadan
Journal:  Thorac Cardiovasc Surg       Date:  2021-12-28       Impact factor: 1.827

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.